What do systematic reviews say?

EDTA vs placebo

EDTA showed no clear difference in myocardial infarction compared with placebo (moderate certainty).

• Chelation therapy for atherosclerotic cardiovascular disease 2020 · Cochrane Headline outcomes only
  RR 0.81 [0.57, 1.14]
  2 studies · 1792 participants
  Moderate

EDTA vs placebo

It is very uncertain whether EDTA changes angina compared with placebo (very low certainty).

• Chelation therapy for atherosclerotic cardiovascular disease 2020 · Cochrane Headline outcomes only
  RR 0.95 [0.55, 1.67]
  2 studies · 1792 participants
  Very low

EDTA vs placebo

EDTA showed no clear difference in stroke compared with placebo (low certainty).

• Chelation therapy for atherosclerotic cardiovascular disease 2020 · Cochrane Headline outcomes only
  RR 0.88 [0.4, 1.92]
  2 studies · 1867 participants
  Low

EDTA vs placebo

• Chelation therapy for atherosclerotic cardiovascular disease 2020 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 181 participants
  Low

EDTA vs placebo

• Chelation therapy for atherosclerotic cardiovascular disease 2020 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 165 participants
  Low

Phlebotonics vs placebo?

Do phlebotonics improve signs and symptoms of venous insufficiency… probably leads to lower oedema in the lower legs (dichotomous variable) compared with placebo? (moderate certainty).

• Phlebotonics for venous insufficiency 2020 · Cochrane Headline outcomes only
  RR 0.7 [0.63, 0.78]
  13 studies · 1245 participants
  Moderate

Phlebotonics vs placebo?

• Phlebotonics for venous insufficiency 2020 · Cochrane Headline outcomes only
  no estimate extracted
  15 studies · 2010 participants
  Moderate

Phlebotonics vs placebo?

• Phlebotonics for venous insufficiency 2020 · Cochrane Headline outcomes only
  no estimate extracted
  5 studies · 1639 participants
  Moderate

Phlebotonics vs placebo?

Do phlebotonics improve signs and symptoms of venous insufficiency… showed no clear difference in ulcer healing (dichotomous variable) compared with placebo? (low certainty).

• Phlebotonics for venous insufficiency 2020 · Cochrane Headline outcomes only
  RR 0.94 [0.79, 1.13]
  6 studies · 461 participants
  Low

Phlebotonics vs placebo?

Do phlebotonics improve signs and symptoms of venous insufficiency… probably leads to higher adverse events compared with placebo? (moderate certainty).

• Phlebotonics for venous insufficiency 2020 · Cochrane Headline outcomes only
  RR 1.14 [1.02, 1.27]
  37 studies · 5789 participants
  Moderate

Pentoxifylline vs placebo

• Pentoxifylline for intermittent claudication 2020 · Cochrane Headline outcomes only
  no estimate extracted
  11 studies · 1890 participants
  Low

Pentoxifylline vs placebo

• Pentoxifylline for intermittent claudication 2020 · Cochrane Headline outcomes only
  no estimate extracted
  14 studies · 2110 participants
  Low

Pentoxifylline vs placebo

• Pentoxifylline for intermittent claudication 2020 · Cochrane Headline outcomes only
  no estimate extracted
  5 studies · 902 participants
  Moderate

Pentoxifylline vs placebo

• Pentoxifylline for intermittent claudication 2020 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 1179 participants
  Moderate

Pentoxifylline vs placebo

• Pentoxifylline for intermittent claudication 2020 · Cochrane Headline outcomes only
  no estimate extracted
  9 studies · 1837 participants
  Low

DOAC vs placebo

DOAC showed no clear difference in symptomatic VTE compared with placebo (low certainty).

• Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy 2020 · Cochrane Headline outcomes only
  RR 0.43 [0.18, 1.06]
  3 studies · 1526 participants
  Low

DOAC vs placebo

DOAC showed no clear difference in major bleeding compared with placebo (moderate certainty).

• Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy 2020 · Cochrane Headline outcomes only
  RR 1.74 [0.82, 3.68]
  3 studies · 1494 participants
  Moderate

DOAC vs placebo

DOAC showed no clear difference in symptomatic PE compared with placebo (low certainty).

• Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy 2020 · Cochrane Headline outcomes only
  RR 0.38 [0.1, 1.47]
  3 studies · 1526 participants
  Low

Ultra‐low‐molecular‐weight heparin vs placebo

Ultra‐low‐molecular‐weight heparin leads to lower symptomatic VTE compared with placebo (high certainty).

• Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy 2020 · Cochrane Headline outcomes only
  RR 0.36 [0.22, 0.6]
  1 study · 3212 participants
  High

Ultra‐low‐molecular‐weight heparin vs placebo

Ultra‐low‐molecular‐weight heparin showed no clear difference in major bleeding compared with placebo (moderate certainty).

• Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy 2020 · Cochrane Headline outcomes only
  RR 1.05 [0.55, 2]
  1 study · 3172 participants
  Moderate